Health & Fitness
Health and Fitness
Health and Fitness
Mon, August 3, 2009
Sat, August 1, 2009
Fri, July 31, 2009
Thu, July 30, 2009
Wed, July 29, 2009 AVI BioPharma, Inc.: AVI BioPharma, Inc. to Present at IBC Drug Discovery & Development Conference: Oligonucleotide Therapeutic
CORVALLIS, OR--(Marketwire - July 29, 2009) - AVI BioPharma, Inc. (
Hong Moulton, Ph.D., Director of Discovery Research, is invited to present on Monday, Aug. 3. Her talk "Peptide-Mediated Muscle Delivery of Morpholino Oligomers for Treatment of Duchenne Muscular Dystrophy" will feature an overview of the Company's peptide-conjugated morpholino oligomer (PPMO) technology for treatment of this disease.
Duchenne muscular dystrophy (DMD) is caused by mutations in the human dystrophin gene. The potential utility of PPMO chemistry for the systemic treatment of DMD has been demonstrated in mouse and non-human primate models. Preclinical studies have shown that the PPMO conjugates entered muscle cells, caused targeted exon-skipping, restored dystrophin, and reduced pathology and improved function of muscles. Results from a single dose escalation clinical study of AVI-4658, a PMO therapeutic, demonstrate that a single intramuscular (IM) showed that injection of the drug into a small foot muscle of several DMD patients successfully induced dystrophin production in each patient as compared to placebo treated muscle in the contralateral foot.
Drug Discovery & Development Week in Boston, MA includes five targeted scientific conferences featuring strategies and forward-looking approaches to help attendees accelerate small molecules, antibody therapeutics and oligonucleotide therapeutics from early discovery to the clinic.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA-based therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit [ www.avibio.com ].
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.
